Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar;4(3):397-412.
doi: 10.18632/oncotarget.924.

Linked-in: design and efficacy of antibody drug conjugates in oncology

Jonathan Feld  1 , Stefan K Barta, Carolina Schinke, Ira Braunschweig, Yiyu Zhou, Amit K Verma
Affiliations

Linked-in: design and efficacy of antibody drug conjugates in oncology

Jonathan Feld et al. Oncotarget. 2013 Mar.

Abstract

The use of antibody drug conjugates (ADCs) as targeted chemotherapies has successfully entered clinical practice and holds great promise. ADCs consist of an antibody and toxin-drug combined together via a chemical linker. While the antibody and drug are of vital importance in the direct elimination of cancer cells, more advanced linker technology was instrumental in the delivery of more potent drugs with fewer side effects. Here, we discuss the preclinical experience as well as clinical trials, with a specific emphasis on the clinical outcomes and side effects, in addition to linker strategies for five different ADCs, in order to describe different approaches in the development of this new class of anticancer agents. Brentuximab vedotin is approved for use in Hodgkin's lymphoma and Trastuzumab emtansine is approved for breast cancer. Combotox, Inotuzumab Ozogamicin, and Moxetumomab Pasudotox are in various stages of clinical development and are showing significant efficacy in lymphoid malignancies. These ADCs illustrate the promise and future potential of targeted therapy for presently incurable malignancies.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Timeline delineating the evolution of antibody-drug conjugate discovery and therapy in cancer therapeutics [3-6]
ADC: Antibody-drug conjugate, mAb: Monoclonal antibody, DLBCL: Diffuse large B cell lymphoma, DD: Denileukin Difitox, CTCL: Cutaneous T cell lymphoma, GO: Gentuzumab Ozogamicin, AML: Acute myeloid leukemia, r/r: relapsed and/or refractory, HL: Hodgkin's lymphoma, sALCL: Systemic anaplastic large-cell lymphoma, FDA: Food and Drug Administration, Her2: Human Epidermal Growth Factor Receptor 2, MBC: Metastatic breast cancer.
Figure 2
Figure 2. Composition and mode of action of antibody-drug-conjugates (ADC)
A) An ADC is composed of a monoclonal antibody directed against a specific epitope on a target cell. A cytotoxic compound is attached to the antibody via a linker. B) Once administered, the antibody component of the ADC binds to the targeted cell receptor, which enables the ADC to be internalized (usually via endocytosis) and subsequently degraded. The released toxin causes cell death via various mechanisms depending on the toxin, such as DNA damage or inhibiting protein translation.
See this image and copyright information in PMC

References

    1. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8(6):473–480. - PubMed
    1. Mathe G, LO TB, Bernard J. Effect on mouse leukemia 1210 of a combination by diazo-reaction of amethopterin and gamma-globulins from hamsters inoculated with leukemia by heterografts. C R Hebd Seances Acad Sci. 1958;246(10):1626–1628. - PubMed
    1. Piascik PP. FDA approves fusion protein for treatment of lymphoma. J Am Pharm Assoc (Wash) 1999;39(4):571–572. - PubMed
    1. Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Current Opinion in Oncology. 1998;10(6):548–551. - PubMed
    1. Hussain N. Ligand-mediated tissue specific drug delivery. Advanced Drug Delivery Reviews. 2000;43(2–3):95–100. - PubMed

MeSH terms